Korean clinical practice guidelines on biologics for moderate to severe Crohn?s diseaseopen access
- Authors
- Koh, Seong-Joon; Hong, Sung Noh; Park, Soo-Kyung; Ye, Byong Duk; Kim, Kyeong Ok; Shin, Jeong Eun; Yoon, Yong Sik; Lee, Hong Sub; Jung, Sung Hoon; Choi, Miyoung; Na, Soo-Young; Choi, Chang Hwan; Kim, Joo Sung
- Issue Date
- Jan-2023
- Publisher
- KOREAN ASSOC STUDY INTESTINAL DISEASES
- Keywords
- Crohn disease; Guideline; Biologics; Biosimilars
- Citation
- INTESTINAL RESEARCH, v.21, no.1, pp 43 - 60
- Pages
- 18
- Journal Title
- INTESTINAL RESEARCH
- Volume
- 21
- Number
- 1
- Start Page
- 43
- End Page
- 60
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/69256
- DOI
- 10.5217/ir.2022.00029
- ISSN
- 1598-9100
2288-1956
- Abstract
- Crohn's disease (CD) is a relapsing and progressive condition characterized by diarrhea, abdominal pain, weight loss, and hematochezia that results in serious complications such as perforations, fistulas, and abscesses. Various medications, interventions, and surgical treatments have been used to treat CD. The Korean guidelines for CD management were distributed in 2012 and revised in 2017 by the Inflammatory Bowel Disease (IBD) Research Group of the Korean Association for the Study of Intestinal Diseases. Substantial progress in mucosal immunologic research has elucidated the pathophysiology of IBD, leading to development of biological agents for treatment of CD. The first developed biologic agent, tumor necrosis factor-alpha agents, were shown to be efficacious in CD, heralding a new era in management of CD. Subsequently, vedolizumab, a monoclonal antibody against integrin alpha 4 beta 7, and ustekinumab, a human monoclonal antibody that inhibits the common p40 subunit of interleukin-12 and interleukin-23, were both approved for clinical use and are efficacious and safe for both induction and maintenance of remission in moderate-to-severe CD patients. Moreover, a recent study showed the non-inferiority of CT-P13, an infliximab biosimilar, compared with infliximab in CD patients. The third Korean guidelines for CD management provide updated information regarding treatment of moderate-to-severe CD patients with biologic agents. (Intest Res, Published online )
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - ETC > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/69256)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.